产品
编 号：F742702
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1143503-67-6
产品详情
生物活性：
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus.
体内研究：
Tabalumab (500 μg/rat; s.c.; single) leads to decreased B-cells and a reduction in non-canonical nF-κB signaling.Animal Model:Human BAFF Tg mice.
Dosage:500 μg/rat
Administration:Subcutaneous injection, single.
Result:Significantly decreased the splenic B-cell count between day 4 and 8.Decreased levels of p52, which returned to near the BAFF Tg level at Day 23.
体外研究：
Tabalumab (1-100 ng/mL; 44 h) neutralizes soluble and membrane-bound BaFF both in T1165.17 cells and (1 μg/mL; 3 days) CD19+B-cells.Tabalumab (50 μg/mL; 15 min) inhibits BaFF binding to BR3, TacI, and BcMa in HEK293 cells.
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus.
体内研究：
Tabalumab (500 μg/rat; s.c.; single) leads to decreased B-cells and a reduction in non-canonical nF-κB signaling.Animal Model:Human BAFF Tg mice.
Dosage:500 μg/rat
Administration:Subcutaneous injection, single.
Result:Significantly decreased the splenic B-cell count between day 4 and 8.Decreased levels of p52, which returned to near the BAFF Tg level at Day 23.
体外研究：
Tabalumab (1-100 ng/mL; 44 h) neutralizes soluble and membrane-bound BaFF both in T1165.17 cells and (1 μg/mL; 3 days) CD19+B-cells.Tabalumab (50 μg/mL; 15 min) inhibits BaFF binding to BR3, TacI, and BcMa in HEK293 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备